Lake Street Lowers Pulmonx Price Target to $8.00, Maintains "Buy" Rating

Lake Street analyst Frank Takkinen maintained the "Buy" rating for Pulmonx (LUNG) while lowering the price target from $12.00 to $8.00. This adjustment corresponds to a 33.33% decrease in the price target. The Pulmonx stock has seen several analyst actions, highlighting varying perspectives on the company's market performance. Based on the consensus recommendation, Pulmonx's average brokerage recommendation is 2.2, indicating "Outperform" status. The estimated GF Value for Pulmonx in one year is $16.26, suggesting a 783.7% upside from the current price.

Title: Pulmonx (LUNG) Stock Price Target Revised by Lake Street Analyst

July 2, 2025 - Lake Street analyst Frank Takkinen has revised the price target for Pulmonx (LUNG) from $12.00 to $8.00, while maintaining a "Buy" rating on the stock. This adjustment corresponds to a 33.33% decrease in the price target, reflecting a more conservative outlook on the company's future performance.

The revision comes amid updated revenue projections for 2025, where Pulmonx now anticipates a revenue growth rate of 7%-10%, down from its earlier forecast of 15%-17%. The analyst describes this adjustment as a "prudent reset" by the company. Despite the downward revision, the consensus recommendation for Pulmonx remains "Outperform," with an average brokerage recommendation of 2.2.

Pulmonx Corporation, a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD), reported robust financial performance in the second quarter of 2025. The company's product portfolio includes the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System, and the LungTraX Platform.

However, the company faces significant challenges in profitability, with an operating margin of -66% and a net margin of -65.27%. The gross margin stands at 10.57%. The company's strategic focus on innovative COPD treatments positions it uniquely within the competitive landscape of the healthcare sector.

The estimated GF Value for Pulmonx in one year is $16.26, suggesting a 783.7% upside from the current price. The company's market capitalization is approximately $77.7 million, with a strong presence in key markets such as the United States, Europe, the Middle East, Africa, and the Asia Pacific region.

The stock's recent performance and analyst actions highlight varying perspectives on Pulmonx's market performance. While some analysts remain optimistic, others have adjusted their expectations in light of the company's updated revenue projections.

References:
[1] https://stockanalysis.com/stocks/lung/
[2] https://www.gurufocus.com/news/3022583/pulmonx-lung-price-target-reduced-amidst-adjusted-revenue-forecast